BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2013

Jan 7, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2013-01-01

Reporting Person: Babu Yarlagadda S (VP Drug Discovery)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-01-01	Common Stock	A	8500	—	Acquired	148435	Direct
2013-01-01	Common Stock	A	8500	—	Acquired	156935	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-01-01	Emp. Stock Option (Right to Buy)	$1.42	A	50000	Acquired	2023-01-01	Common Stock (50000)	Direct
2013-01-01	Emp. Stock Option (Right to Buy)	$1.42	A	50000	Acquired	2023-01-01	Common Stock (50000)	Direct

Footnotes

F1: Retention Restricted Stock Award. Will vest 50% on each of the first and second anniversaries of the date of grant.

F2: Annual Employee Restricted Stock Award. Will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

F3: Annual Employee Option Grant becomes exercisable at the rate of 25% of each of the first, second, third and fourth anniversaries of the date of grant.

F4: Retention Employee Stock Option becomes exercisable at a rate of 50% on each of the final and second anniversaries of the date of grant.